Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.23 (
MMP
)
4,246
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
4-(Methylmercapto)-phenol (
MMP
) and 4-(methylsulfinyl)-phenol (
MSP
) are oxidized by the soil isolate Nocardia spec. DSM 43251, which is closely related to Nocardia calcarea. The rate of degradation depends on the capability of a substrate to support growth and is strongly enhanced in the presence of a second carbon source under the conditions of cooxidation.
MMP
and
MSP
are cometabolized by hydroxylation of the benzene ring with the formation of the substituted catechol following by ring cleavage between carbon atoms 2 and 3 ("meta" fission) to give 2-hydroxy-5-methylmercapto-or-2-hydroxy-5-methylsulfinylmuconic semialdehyde. Oxidation of
MMP
to
MSP
represents a bypath of
MMP
-oxidation. The intermediates were identified on the basis of their physical properties. The enzymes responsible for the metabolism of
MMP
and
MSP
are induced by growth with
MMP
or
MSP
, but not with glucose.
MMP
-and
MSP
-induced cells catalyze the oxidation of a variety of substituted phenols. This indicates a rather low substrate specificity of the enzymes induced by
MMP
and
MSP
.
...
PMID:Bacterial metabolism of substituted phenols. Oxidation of 4-(methylmercapto)-and 4-(methylsulfinyl)-phenol by Nocardia spec. DSM 43251. 90 25
The suggested model for pro-matrix metalloproteinase-2 (proMMP-2) activation by membrane type 1
MMP
(MT1-MMP) implicates the complex between MT1-
MMP
and tissue inhibitor of MMP-2 (TIMP-2) as a receptor for proMMP-2. To dissect this model and assess the pathologic significance of MMP-2 activation, an artificial receptor for proMMP-2 was created by replacing the signal sequence of TIMP-2 with cytoplasmic/transmembrane domain of type II transmembrane mosaic serine protease (
MSP
-T2). Unlike TIMP-2,
MSP
-T2 served as a receptor for proMMP-2 without inhibiting MT1-
MMP
, and generated TIMP-2-free active MMP-2 even at a low level of MT1-
MMP
. Thus,
MSP
-T2 did not affect direct cleavage of the substrate testican-1 by MT1-
MMP
, whereas TIMP-2 inhibited it even at the level that stimulates proMMP-2 processing. Expression of
MSP
-T2 in HT1080 cells enhanced MMP-2 activation by endogenous MT1-
MMP
and caused intensive hydrolysis of collagen gel. Expression of
MSP
-T2 in U87 glioma cells, which express a trace level of endogenous MT1-
MMP
, induced MMP-2 activation and enhanced cell-associated protease activity, activation of extracellular signal-regulated kinase, and metastatic ability into chick embryonic liver and lung. MT1-
MMP
can exert both maximum MMP-2 activation and direct cleavage of substrates with
MSP
-T2, which cannot be achieved with TIMP-2. These results suggest that MMP-2 activation by MT1-
MMP
potentially amplifies protease activity, and combination with direct cleavage of substrate causes effective tissue degradation and enhances tumor invasion and metastasis, which highlights the complex role of TIMP-2.
MSP
-T2 is a unique tool to analyze physiologic and pathologic roles of MMP-2 and MT1-
MMP
in comparison with TIMP-2.
...
PMID:Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2. 1897 56
An artificial receptor for proMMP-9 was created by fusing tissue inhibitor of MMP-1 (TIMP-1) with type II transmembrane mosaic serine protease (
MSP
-T1). Expression of
MSP
-T1 in 293T cells induced binding of proMMP-9, which was processed by MMP-2 activated by membrane type 1
MMP
(MT1-MMP). HT1080 cells transfected with the
MSP
-T1 gene produced activated MMP-9 in collagen gel, and addition of proMMP-2 to the culture augmented it, which resulted in intensive collagen digestion. These cells metastasized into chick embryonic liver more than control cells. Treatment of HT1080 cells with concanavalin A in the presence of exogenous proMMP-2 induced activation of not only proMMP-2 but also proMMP-9. Knockdown of MT1-
MMP
or TIMP-2 expression with siRNA suppressed activation of both proMMP-2 and proMMP-9. Transfection of TIMP-1 siRNA suppressed cell binding and activation of proMMP-9, but not proMMP-2 activation. Knockdown of a disintegrin and metalloproteinase 10 (ADAM10) expression reduced cell binding and processing of proMMP-9. These results suggest that proMMP-9, which binds to a receptor complex containing TIMP-1 and ADAM10, is activated by the MT1-
MMP
/MMP-2 axis, and MMP-9 thus activated stimulates cellular proteolysis and metastasis.
...
PMID:Activation of MMP-9 by membrane type-1 MMP/MMP-2 axis stimulates tumor metastasis. 2798 67
An increased surface level of CIE (clathrin-independent endocytosis) proteins is a new feature of malignant neoplasms. CD147 is a CIE glycoprotein highly up-regulated in hepatocellular carcinoma (HCC). The ability to sort out the early endosome and directly target the recycling pathway confers on CD147 a prolonged surface half-life. However, current knowledge on CD147 trafficking to and from the cell-surface is limited. In this study, an
MSP
(membrane and secreted protein)-cDNA library was screened against EpoR/LR-F3/CD147EP-expressed cells by MAPPIT (mammalian protein-protein interaction trap). CD147 co-expressing with the new binder was investigated by GEPIA (gene expression profiling interactive analysis). The endocytosis, ER-Golgi trafficking and recycling of CD147 were measured by confocal imaging, flow cytometry, and biotin-labeled chase assays, respectively. Rab GTPase activation was checked by GST-RBD pull-down and
MMP
activity was measured by gelatin zymography. HCC malignant phenotypes were determined by cell adhesion, proliferation, migration, Transwell motility, and invasion assays. An ER-Golgi-resident transmembrane protein YIPF2 was identified as an intracellular binder to CD147. YIPF2 correlated and co-expressed with CD147, which is a survival predictor for HCC patients. YIPF2 is critical for CD147 glycosylation and trafficking functions in HCC cells. YIPF2 acts as a Rab-GDF (GDI-displacement factor) regulating three independent trafficking steps. First, YIPF2 recruits and activates Rab5 and Rab22a GTPases to the endomembrane structures. Second, YIPF2 modulates the endocytic recycling of CD147 through distinctive regulation on Rab5 and Rab22a. Third, YIPF2 mediates the mature processing of CD147 via the ER-Golgi trafficking route. Decreased YIPF2 expression induced a CD147 efficient delivery to the cell-surface, promoted
MMP
secretion, and enhanced the adhesion, motility, migration, and invasion behaviors of HCC cells. Thus, YIPF2 is a new trafficking determinant essential for CD147 glycosylation and transport. Our findings revealed a novel YIPF2-controlled ER-Golgi trafficking signature that promotes CD147-medated malignant phenotypes in HCC.
...
PMID:YIPF2 is a novel Rab-GDF that enhances HCC malignant phenotypes by facilitating CD147 endocytic recycle. 3118 79